
|Articles|June 6, 2017
Chesapeake IRB Acquires Institutional Biosafety Corporation
Advertisement
Chesapeake IRB, the technology-enabled independent institutional review board (IRB) serving the clinical research industry, announced its acquisition of Institutional Biosafety Corporation (IBC), a provider of institutional biosafety committee services located in Rockville, MD.
The acquisition now expands Chesapeake’s services with the ability to deliver comprehensive review and oversight of research using recombinant or synthetic DNA molecules, including clinical trials involving genetic engineering and gene therapy.
Read the full release
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck
2
ACT Brief: Cross-Asset Site Partnerships, Vaccine Trial Standardization, and Ovarian Cancer Care Gaps
3
SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years
4
A Shot in the Arm to Traditional Vaccine Trial Strategy
5



